Tongue cancer natural history, complications and prognosis

Revision as of 01:40, 29 November 2015 by Simrat Sarai (talk | contribs)
Jump to navigation Jump to search

Tongue cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Tongue cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Tongue cancer natural history, complications and prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Tongue cancer natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Tongue cancer natural history, complications and prognosis

CDC on Tongue cancer natural history, complications and prognosis

Tongue cancer natural history, complications and prognosis in the news

Blogs on Tongue cancer natural history, complications and prognosis

Directions to Hospitals Treating Tongue cancer

Risk calculators and risk factors for Tongue cancer natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Simrat Sarai, M.D. [2]

Overview

If left untreated, patients with tongue cancer may progress to develop metastasis. Common complications of treatment of tongue cancer include neurotoxicity, bleeding, radiation caries, trismus, osteonecrosis, oral mucositis, chronic dysphagia, anemia, pharyngocutaneous fistula, aspiration, infections, xerostomia, taste alterations, nutritional compromise, and abnormal tooth development. Prognosis is generally good, and the five-year mortality rate of patients with stage I and II tongue cancer is approximately 89 and 95 respectively. The five- year disease specific survival rate of patients with stage III and IV cancers is 39 and 27 percent respectively.

Natural History

Carcinomas of the tongue base are clinically silent until they deeply infiltrate the tongue musculature. They are usually less differentiated. Because of the difficulties with direct visualization, they may extend into the oral tongue or have clinical lymph metastases before the diagnosis is established. As the tumors enlarge, they may cause a mass effect which can lead to respiratory compromise when the patient presents late in their illness.

Complications

  • Complications of chemotherapy includes the following:
    • Neurotoxicity- This complication is a side effect of certain classes of drugs, such as the vinca alkaloids.
    • Bleeding
  • Complications of radiation therapy includes the following:
    • Radiation caries
    • Trismus
    • Osteonecrosis
    • Osteoradionecrosis
  • Complications common to both chemotherapy and radiation include the following:
    • Oral mucositis
    • Chronic dysphagia
    • Anemia
    • Pharyngocutaneous fistula
    • Aspiration
    • Infections such as viral, bacterial, and fungal that results from myelosuppression, xerostomia, and damage to the mucosa from radiotherapy or chemotherapy
    • Xerostomia
    • Functional disabilities such as impaired ability to swallow, eat, taste and speak because of trismus, dry mouth, mucositis, and infection
    • Taste alterations such as changes in taste perception of food.
    • Nutritional compromise such as poor nutrition from eating difficulties caused by dry mouth, mucositis, dysphagia, and loss of taste.
    • Abnormal dental development
      • Altered tooth development, craniofacial growth, or skeletal development in children secondary to high doses of chemotherapy and/or radiotherapy before age 9.

Prognosis

Depending on the extent of the tumor at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as good. The five- year mortality rate of patients with stage I and II cancers is 89 and 95 percent. The five-year survival rate calculated from a population-based database is reported as, 67 and 51 percent, respectively[1][2] The five- year disease specific survival rate of patients with stage III and IV cancers is 39 and 27 percent respectively.[3] Cancer of the tongue has been associated with a worse prognosis compared with other oral cavity subsites in some series.[4][5] In younger patients (ie, less than 40 years) the tongue cancer is found to have a more aggressive course.[6]

The prognosis of tongue cancer depends on the location and stage of the cancer. The five year survival rate for individuals diagnosed with Stage I, II, III, and IV is shown below:

Stage of the tongue cancer Five-year survival rate
Stage I

71%

Stage II

59%

Stage III

47%

Stage IV

37%

In 2011, approximately 25.69% of all oral cancer deaths were from tongue cancer. According to National Cancer Institute, from 2004-2008 the average age of death from tongue cancer was 66. Approximate age of diagnosis of tongue cancer and percentage of deaths from tongue cancer are shown below in this table:

Age of diagnosis of tongue cancer Percentage of deaths from tongue cancer
≤20

0.1%

Age 20- 34

1.1%

Age 35- 44

3.9%

Age 45- 54

15.4%

Age 55- 64

24.8%

Age 65- 74

23.8%

Age 75- 84

20.3%

≥85

10.7%

References

  1. W. L. Jr Hicks, J. H. Jr North, T. R. Loree, S. Maamoun, A. Mullins, J. B. Orner, V. Y. Bakamjian & D. P. Shedd (1998). "Surgery as a single modality therapy for squamous cell carcinoma of the oral tongue". American journal of otolaryngology. 19 (1): 24–28. PMID 09470947. Unknown parameter |month= ignored (help)
  2. Kyle Rusthoven, Ari Ballonoff, David Raben & Changhu Chen (2008). "Poor prognosis in patients with stage I and II oral tongue squamous cell carcinoma". Cancer. 112 (2): 345–351. doi:10.1002/cncr.23183. PMID 018041071. Unknown parameter |month= ignored (help)
  3. Donald G. Sessions, Gershon J. Spector, Jason Lenox, Bruce Haughey, Clifford Chao & James Marks (2002). "Analysis of treatment results for oral tongue cancer". The Laryngoscope. 112 (4): 616–625. doi:10.1097/00005537-200204000-00005. PMID 012150512. Unknown parameter |month= ignored (help)
  4. M. J. Zelefsky, L. B. Harrison, D. E. Fass, J. Armstrong, R. H. Spiro, J. P. Shah & E. W. Strong (1990). "Postoperative radiotherapy for oral cavity cancers: impact of anatomic subsite on treatment outcome". Head & neck. 12 (6): 470–475. PMID 02258285. Unknown parameter |month= ignored (help)
  5. R. Bryan Bell, Deepak Kademani, Louis Homer, Eric J. Dierks & Bryce E. Potter (2007). "Tongue cancer: Is there a difference in survival compared with other subsites in the oral cavity?". Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons. 65 (2): 229–236. doi:10.1016/j.joms.2005.11.094. PMID 017236926. Unknown parameter |month= ignored (help)
  6. T. O. Truitt, L. L. Gleich, G. P. Huntress & J. L. Gluckman (1999). "Surgical management of hard palate malignancies". Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery. 121 (5): 548–552. PMID 010547468. Unknown parameter |month= ignored (help)